Regulatory Milestone
, founded by , announced it received 's "Breakthrough Device Designation" for its Blindsight device, aimed at restoring vision even to those who have lost their eyes and optic nerve.
The FDA's program accelerates the development and review of devices for life-threatening or irreversibly debilitating conditions, underscoring the potential impact of Neuralink's work.
Technological Claims and Skepticism
Musk claims Blindsight could eventually enable enhanced vision capabilities, including seeing in infrared and ultraviolet, despite initial low-resolution output.
Critics highlight the technological limitations, noting that past attempts at restoring vision with similar devices have resulted in fuzzy and imperfect sight, challenging Musk's optimistic projections.